NEW YORK (GenomeWeb News) – Myriad Genetics will adopt RainDance Technologies' microdroplet PCR-based target enrichment technology for use in a next-generation sequencing-based hereditary cancer panel test that Myriad is currently developing, the companies said today.

Under a multi-year supply agreement, RainDance will provide Myriad with ThunderStorm target enrichment systems, reagents, gene panels, and consumables.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."